Take a look at our previous reports:

Our R&D portfolio

We continue to leverage our science and target discovery engine to further broaden our portfolio of candidate medicines. In our pipeline currently 10 programs are in lead optimization, 5 preclinical programs are developed towards testing in humans and 7 are in clinical stage programs.

Deep R&D portfolio

Deep R&D portfolio (graphic)
* LO: Lead optimization